A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION
Contact:
NCT Number:
Protocol:
AAAS3594
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain types of metastatic cutaneous squamous cell carcinoma (CSCC) (one of the main types of skin cancer ) or locally advanced CSCC (who are not candidates for curative surgery or curative radiation). REGN5678 has not yet been studied in people.
Are you Eligible? (Inclusion Criteria)
- The purpose of this study is to determine the safety, tolerability (how your
- body reacts to the drug) and effectiveness of REGN5678 which will be given
- alone first and then be given in combination with cemiplimab. Neither REGN5678
- nor Cemiplimab is FDA approved to treat your type of cancer. Cemiplimab is
- approved by the FDA for the treatment of certain types of metastatic cutaneous
- squamous cell carcinoma (CSCC) (one of the main types of skin cancer ) or
- locally advanced CSCC (who are not candidates for curative surgery or curative
- radiation). REGN5678 has not yet been studied in people.
Specialty Area(s)
Prostate Cancer, Immunotherapy
